Napoleone Ferrara
拿破仑·费拉拉
MD
Distinguished Professor, Department of Pathology; Moores Cancer Center病理学系杰出教授；穆尔斯癌症中心
👥Biography 个人简介
Napoleone Ferrara discovered VEGF (vascular endothelial growth factor) in 1989 and led development of bevacizumab (Avastin), the first FDA-approved anti-angiogenic cancer therapy. His work fundamentally transformed understanding of tumor vascularization and spawned an entire class of targeted therapies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
VEGF Discovery & Characterization
Isolated and cloned VEGF in 1989, establishing it as the primary driver of pathological angiogenesis in tumors and laying the molecular foundation for all subsequent anti-VEGF therapeutic strategies.
Bevacizumab Development
Led preclinical and translational research that resulted in bevacizumab (Avastin), FDA-approved in 2004 for colorectal cancer—the first anti-angiogenic antibody approved for oncology.
Representative Works 代表性著作
Vascular endothelial growth factor is a secreted angiogenic mitogen
Science (1989)
Landmark paper reporting the discovery and cloning of VEGF, establishing its role as the primary mediator of tumor-driven angiogenesis.
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
Nature (1993)
Demonstrated that anti-VEGF antibodies suppress tumor growth in vivo, providing direct preclinical rationale for bevacizumab development.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 拿破仑·费拉拉 的研究动态
Follow Napoleone Ferrara's research updates
留下邮箱，当我们发布与 Napoleone Ferrara（University of California San Diego）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment